Related Experiment Video
Updated: Feb 7, 2026

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
Published on: July 21, 2023
Heart Failure and Stroke
Katja Schumacher1,2, Jelena Kornej2,3, Eduard Shantsila1
1Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK.
Insights
Heart failure (HF) patients face a high risk of ischemic stroke, especially with atrial fibrillation (AF). The CHA₂DS₂-VASc score may help stratify stroke risk in HF patients, guiding prevention strategies.
Area of Science:
- Cardiology
- Neurology
- Internal Medicine
Background:
- Ischemic stroke is a major cause of death and disability in heart failure (HF) patients.
- The presence of atrial fibrillation (AF) significantly elevates stroke risk in HF.
- Asymptomatic (silent) AF paroxysms complicate risk stratification in HF patients.
Purpose of the Study:
- To review stroke risk in heart failure patients.
- To discuss risk stratification methods for stroke in HF.
- To outline stroke prevention strategies for HF patients.
Main Methods:
- Review of current literature on stroke risk in heart failure.
- Analysis of the utility of the CHA₂DS₂-VASc score in HF patients.
- Examination of independent risk factors for stroke in HF.
Main Results:
- The CHA₂DS₂-VASc score shows predictive value for stroke in HF patients, irrespective of AF.
- Hypertension, diabetes mellitus, and prior stroke are identified independent risk factors.
- Heart failure itself is an independent risk factor for stroke.
- Oral anticoagulation is recommended for HF patients with AF.
- Individualized risk stratification is preferred for HF patients without AF.
Conclusions:
- The CHA₂DS₂-VASc score may aid in routine stroke risk prediction for HF patients with or without AF.
- Current guidelines favor non-vitamin K antagonist anticoagulants over warfarin.
- Further research may refine stroke prevention strategies in HF populations.
Purpose:
Ischemic stroke significantly contributes to morbidity and mortality in heart failure (HF). The risk of stroke increases significantly, with coexisting atrial fibrillation (AF). An aggravating factor could be asymptomatic paroxysms of AF (so-called silent AF), and therefore, the risk stratification in these patients remains difficult. This review provides an overview of stroke risk in HF, its risk stratification, and stroke prevention in these patients.
Recent Findings:
Stroke risk stratification in HF patients remains an important issue. Recently, the CHA2DS2-VASc score, originally developed to predict stroke risk in AF patients, had been reported to be a predictive for strokes in HF patients regardless of AF being present. Furthermore, there are several independent risk factors (e.g., hypertension, diabetes mellitus, prior stroke) described. Based on the current evidence, HF should be considered as an independent risk factor for stroke. The CHA2DS2-VASc score might be useful to predict stroke risk in HF patients with or without AF in clinical routine. However, there is only a recommendation for the oral anticoagulation use in patients with concomitant HF and AF, while in patients with HF and no AF, individualized risk stratification is preferred. Current guidelines recommend to prefer non-vitamin Kantagonist anticoagulants over warfarin.
Related Concept Videos
Heart Failure II: Pathophysiology
Pathophysiology of Heart Failure
Heart Failure I: Introduction
Heart Failure VI: Adjunct Therapies
Heart Failure Drugs: Diuretics
Heart Failure V: Medical Management

